The 18-team field is set for the 2024 edition of the MLS Cup Playoffs. After setting a league record for the most points scored in a single season, Inter Miami CF will have home-field advantage ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33. Operator: Good afternoon, everyone, and welcome to Personalis Third Quarter 2024 ...

Check out some anticipated series in the video above or the slideshow gallery below, followed by the full list of new Fall season 2024 anime and where to watch them in the U.S. and their ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

esmo group has launched its latest product—the Apollo Quad Handler. Designed to bridge the gap between the engineering and ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...

We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

Portland voters wanted new options. Now we have them—so, so many of them. When ballots arrive in mailboxes this week, Portlanders will be confronted with a list of candidates the length of a ...

The Company presented interim results from the TAMARACK study at the European Society for Medical Oncology (ESMO) Congress in September 2024 and expects to have mature median radiographic ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data.